News >

Accurate Risk Status Assessment Critical to Prostate Cancer Care

Gina Columbus @ginacolumbusonc
Published: Thursday, Aug 25, 2016

Julio Pow-Sang, MD

Julio Pow-Sang, MD

Determining whether a patient with prostate cancer has low- or intermediate-risk disease is a significant distinction to make, as the 2 subsets are managed quite differently, explains Julio Pow-Sang, MD.

during the meeting.

OncLive: Please provide an overview of your lecture on the options for patients with low- and intermediate-risk disease.

Pow-Sang: The goal is to clarify the distinction between risk groups with localized prostate cancer because that drives a lot of the decisions in management. One of the fortunate things happening is that, with better molecular testing and imaging, one is better able to characterize the tumors. Traditionally, cancers that were localized—specifically in prostate cancer—were divided into organ-confined cancer, localized cancer, and locally extensive cancer. That was the extent of the stratification, and it was very difficult to determine what treatment to give.

We also recognize that there is a subset of men who have cancer and are never going to have problems for the rest of their life—and they start dying from something else. Newer tests and a better understanding of the behavior of the cancer have helped us determine who those men are versus the ones who might need treatment.

What are some of the key considerations for oncologists when treating patients?

One of the most important things is to define—as best as one can with the technology available—what risk that the man really falls into. That’s going to drive the discussion about potential management options—whether active surveillance is an option or not. If one defines that the man [has] very low-risk disease, one could feel very comfortable with watching that person and explaining the reasons why.

When dealing with an intermediate-risk patient, we start moving into the area of truly intermediate, high-intermediate, or even going into the high-risk territory—in which one might have to consider clinical trials because conventional treatments are not very good, or one might try to consider more aggressive local treatments, or a combination of treatments.

You mentioned the technology that’s available today. How can this technology be improved?

We have very good technology [now] compared with what we had only 5 or 10 years ago, and it keeps improving. The big push now is to better characterize the tumors by molecular markers. There are several available. There are sets of genes that one can test for and then better determine the behavior of the cancer into the future. One big field is molecular markers of different types; they are tissue, urine, or blood-based markers.


... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x